foxo4-dri senolytic peptide human trial induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation FOXO4-DRI: The Senolytic Peptide That

Together: These two peptides form a powerful regenerative duo combining BPC-157s tissue-protective effects with TB-500s cell-mobilizing action for whole-body healing, faster recovery, and reduced inflammation

People who are looking for longer-lasting relief without the side effects of long-term drug use

Members access evidence-based protocols for immune-modulating peptides, detailed safety guides for autoimmune-specific considerations, dosing calculators tailored to individual needs, and a community of researchers navigating the complex intersection of peptide science and autoimmune disease management

10.1016/j.ejphar.2016.10.035 107 ZlatarM.KokotA.VuleticL